Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (10420)	6/12/1999 4:03:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Iprex is for the cornea, the others for retina. No direct competition, but one could not say that each product will or will not work for the other indication. In the inmmediate future they are not competing which each other. Miravant has a very advance product for macular degeneration, this is retina. QLVT is also in the retina field. The Albumin story is known for clinicians in critical care, I found the links to the Cochrane groups. The Cochrane are one of the best collaboration efforts to interpret research data. I have their reports in the past in print, now I will get it in the net. Thank you for the link.